Chartwell Investment Partners LLC boosted its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 78.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 42,313 shares of the company’s stock after purchasing an additional 18,578 shares during the period. Chartwell Investment Partners LLC owned about 0.09% of Aerie Pharmaceuticals worth $2,010,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of AERI. BlackRock Inc. grew its position in Aerie Pharmaceuticals by 4.5% during the 3rd quarter. BlackRock Inc. now owns 3,124,340 shares of the company’s stock worth $192,304,000 after acquiring an additional 133,239 shares during the last quarter. GSA Capital Partners LLP bought a new position in Aerie Pharmaceuticals during the 3rd quarter worth approximately $369,000. Man Group plc bought a new position in Aerie Pharmaceuticals during the 3rd quarter worth approximately $2,934,000. Point72 Asset Management L.P. grew its position in Aerie Pharmaceuticals by 11.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 203,180 shares of the company’s stock worth $12,506,000 after acquiring an additional 20,880 shares during the last quarter. Finally, Putnam Investments LLC grew its position in Aerie Pharmaceuticals by 177.0% during the 3rd quarter. Putnam Investments LLC now owns 45,748 shares of the company’s stock worth $2,816,000 after acquiring an additional 29,231 shares during the last quarter.
Several equities analysts recently issued reports on AERI shares. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Monday, February 25th. ValuEngine lowered Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Canaccord Genuity set a $65.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, December 20th. Mizuho restated a “buy” rating and set a $77.00 price target on shares of Aerie Pharmaceuticals in a research report on Friday, January 18th. Finally, Oppenheimer set a $64.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, February 26th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company’s stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and an average price target of $76.50.
In other news, insider Casey C. Kopczynski sold 11,000 shares of Aerie Pharmaceuticals stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $46.17, for a total value of $507,870.00. Following the sale, the insider now directly owns 97,243 shares in the company, valued at approximately $4,489,709.31. The sale was disclosed in a filing with the SEC, which is available through this link. 10.53% of the stock is currently owned by company insiders.
Shares of AERI stock opened at $41.33 on Tuesday. Aerie Pharmaceuticals Inc has a fifty-two week low of $32.18 and a fifty-two week high of $74.75.
Aerie Pharmaceuticals Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Featured Story: Blockchain
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.